EZH2 and thyroid tumor: Furthermore, we demonstrated that the combined treatment of sorafenib with miR‐124/506 mimics or EZH2 inhibitor could efficiently improve the sensitivity of sorafenib resistant thyroid tumour cells for sorafenib treatment in vitro and in vivo.